Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo - Abstract

Centre for Infection and Immunity, Division of Clinical Sciences, St George's University of London, London, UK.


In this study, we investigated the effects of combining lenalidomide and docetaxel on in vitro and in vivo models of prostate cancer as a potential strategy for treatment of castrate resistant prostate cancer (CRPC).

The effects of combining lenalidomide and docetaxel on proliferation, apoptosis, invasive potential, anchorage independent growth, and p53 activation in the PC3 and DU145 prostate cell lines were investigated. The effects of the lenalidomide and docetaxel combination on LNCaP prostate cancer cell growth and invasiveness in vitro was also studied. The combination of these two agents was finally tested on a xenograft model of PC3 tumor growth in nude mice.

Lenalidomide decreased the IC50 of docetaxel by up to 50% (P < 0.05) and also decreased invasion in PC3, LNCaP, and DU145 cells and anchorage independent growth in PC3 cells (P < 0.01). Apoptosis in lenalidomide/docetaxel-treated cells was increased by 2.2-fold over single agent docetaxel and a corresponding increase in p53, p38, and BAD activation was observed in Western blots (P < 0.001). When PC3 challenged mice were treated with lenalidomide and docetaxel, median survival increased from 48 to 59 days and the rate of tumor growth was significantly reduced (P < 0.05).

Lenalidomide may be a promising candidate for combination with docetaxel in the treatment of CRPC.

Written by:
Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.   Are you the author?

Reference: Prostate. 2011 Oct 3. Epub ahead of print.
doi: 10.1002/pros.21488

PubMed Abstract
PMID: 21968939

UroToday.com Prostate Cancer Section